A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine
Primary Purpose
Norwalk Gastroenteritis, Norovirus Infections
Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Norovirus Bivalent (GI.1 / GII.4) Vaccine(low)
Norovirus Bivalent (GI.1 / GII.4) Vaccine(middle)
Norovirus Bivalent (GI.1 / GII.4) Vaccine(high)
Normal saline
Aluminum adjuvant
Sponsored by
About this trial
This is an interventional prevention trial for Norwalk Gastroenteritis
Eligibility Criteria
Inclusion Criteria:
- Aged 6 months to 59 years old, can provide legal identification of Chinese population;
- Based on medical history and physical examination, determined by the researcher as healthy;
- Volunteer legal guardians or trustees have the ability to understand (non-illiterate) research procedures, sign informed consent voluntarily with informed consent, and be able to comply with the requirements of clinical research protocols;
- Female subjects of childbearing age were not pregnant at the time of enrollment (negative urine pregnancy test), were not breastfeeding, and had no birth plan within the first 3 months after enrollment; effective contraceptive measures were taken within 2 weeks before enrollment.
Exclusion Criteria:
- Axillary body temperature before inoculation on the day of entry> 37.0 ℃;
- Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc .;
- Have a history of epilepsy, convulsions or convulsions, or a family history of mental illness;
- Those who received immunoenhancement or inhibitor therapy within months (continuous oral or instillation for more than 14 days);
- Have been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases;
- No spleen or spleen function defect caused by any situation;
- Severe liver and kidney disease, drug-uncontrollable hypertension (systolic blood pressure> 140mmHg, diastolic blood pressure> 90mmHg), diabetic complications, malignant tumors, various acute diseases or chronic attacks of acute diseases;
- Have a history of chronic gastrointestinal diseases, diarrhea or other digestive system diseases, and have had gastroenteritis requiring treatment in the past 7 days;.
- Have a history of abnormal coagulation function (such as coagulation factor deficiency, coagulopathy);
- Have a history of severe allergic reactions to vaccination; are allergic to any component of the test vaccine;
- Live attenuated vaccine within14 days; other vaccines received within 7 days;
- Participating in other clinical trials in the near future;
- The investigator judges other circumstances that are not suitable for participation in this clinical trial.
In addition to the general exclusion criteria, specific populations should also adhere to the following exclusion criteria:
- Premature birth (delivery before the 37th week of pregnancy), low weight (birth <2300g) infants under 24 months of age;
- History of salvage, birth apnea, or other causes of salvage, neurological damage, severe chronic disease (such as Down syndrome, sickle cell anemia, or neurological disorders) in children under 24 months of age.
Sites / Locations
- qixian Center for Disease Control and Prevention
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm Type
Experimental
Experimental
Experimental
Placebo Comparator
Placebo Comparator
Arm Label
vaccine group 1
vaccine group 2
vaccine group 3
Normal saline
Aluminum adjuvant
Arm Description
vaccine produced by NVSI , Specification: GI.1 / GII.4 (low), 0.5ml / dose
vaccine produced by NVSI , Specification: GI.1 / GII.4 (middle), 0.5ml / dose
vaccine produced by NVSI , Specification: GI.1 / GII.4 (high), 0.5ml / dose
(0.5ml / dose)produced by NVSI
(0.5ml / dose)produced by NVSI
Outcomes
Primary Outcome Measures
AE of local and systemic reactions within 30 minutes after each dose
All active AEs within 0-7 days after each dose
Active AE: Local and systemic adverse reactions occurring within 0-7 days after each dose of vaccination
All non-active collection AEs within 0-28(30) days after each dose
Adverse events other than active AE include solicitation adverse events reported in addition to the specified solicitation time window
All SAEs within 6 months after the last dose is vaccinated
Secondary Outcome Measures
Calculate geometric mean titer (GMT) of NoV GI.1 and GII.4 IgG antibodies
Calculate positive rate of NoV GI.1 and GII.4 IgG antibodies
Calculate NoV GI.1 and GII.4 HBGA-blocking antibody titers
Calculate NoV GI.1 and GII.4 HBGA-blocking antibody positive rates
Full Information
NCT ID
NCT04188691
First Posted
November 27, 2019
Last Updated
April 20, 2021
Sponsor
National Vaccine and Serum Institute, China
Collaborators
Lanzhou Institute of Biological Products Co., Ltd, Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd., Zhengzhou University
1. Study Identification
Unique Protocol Identification Number
NCT04188691
Brief Title
A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine
Official Title
A Randomized, Blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenulapolymorpha) in Healthy People Aged 6 Months to 59 Years
Study Type
Interventional
2. Study Status
Record Verification Date
April 2020
Overall Recruitment Status
Completed
Study Start Date
November 28, 2019 (Actual)
Primary Completion Date
December 13, 2020 (Actual)
Study Completion Date
December 13, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Vaccine and Serum Institute, China
Collaborators
Lanzhou Institute of Biological Products Co., Ltd, Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd., Zhengzhou University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
A total of 450 subjects were enrolled, divided into four age groups, including 18-59 years, 6-17 years, 3-5 years, and 6-35 months. There are three types of the test vaccine component in each age group. A total of 30 people in each dose group were vaccinated with the test vaccine or placebo 1 or placebo 2, respectively, in a ratio of 3: 1: 1.
The 18-59-year-old, 6-17-year-old, and 3-5-year-old age groups were vaccinated 2 times at a time interval of 28 days. The 6-35 month age group is divided into two groups, Group 1 is inoculated with 2 doses interval of 28 days each, and Group 2 is inoculated with 3 doses interval of 28 days.
Detailed Description
From January to April 2020, this study was affected by the COVID-19 epidemic, which caused the two groups(6-17-year-old,3-5-year-old) of subjects to vaccinate beyond the window and deviate from the experimental plan. After communication between the researcher, the sponsor and the statistician, it was decided to restart the Phase I clinical trials of these two groups.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Norwalk Gastroenteritis, Norovirus Infections
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
510 (Actual)
8. Arms, Groups, and Interventions
Arm Title
vaccine group 1
Arm Type
Experimental
Arm Description
vaccine produced by NVSI , Specification: GI.1 / GII.4 (low), 0.5ml / dose
Arm Title
vaccine group 2
Arm Type
Experimental
Arm Description
vaccine produced by NVSI , Specification: GI.1 / GII.4 (middle), 0.5ml / dose
Arm Title
vaccine group 3
Arm Type
Experimental
Arm Description
vaccine produced by NVSI , Specification: GI.1 / GII.4 (high), 0.5ml / dose
Arm Title
Normal saline
Arm Type
Placebo Comparator
Arm Description
(0.5ml / dose)produced by NVSI
Arm Title
Aluminum adjuvant
Arm Type
Placebo Comparator
Arm Description
(0.5ml / dose)produced by NVSI
Intervention Type
Biological
Intervention Name(s)
Norovirus Bivalent (GI.1 / GII.4) Vaccine(low)
Intervention Description
Norovirus Bivalent (GI.1 / GII.4) Vaccine(low)administered intramuscularly according to a 0, 28,(56) day vaccination schedule
Intervention Type
Biological
Intervention Name(s)
Norovirus Bivalent (GI.1 / GII.4) Vaccine(middle)
Intervention Description
Norovirus Bivalent (GI.1 / GII.4) Vaccine(middle)administered intramuscularly according to a 0, 28,(56) day vaccination schedule
Intervention Type
Biological
Intervention Name(s)
Norovirus Bivalent (GI.1 / GII.4) Vaccine(high)
Intervention Description
Norovirus Bivalent (GI.1 / GII.4) Vaccine(high)administered intramuscularly according to a 0, 28,(56)day vaccination schedule
Intervention Type
Biological
Intervention Name(s)
Normal saline
Intervention Description
Normal saline administered intramuscularly according to a 0, 28 ,(56)day vaccination schedule
Intervention Type
Biological
Intervention Name(s)
Aluminum adjuvant
Intervention Description
Aluminum adjuvant administered intramuscularly according to a 0, 28,(56) day vaccination schedule
Primary Outcome Measure Information:
Title
AE of local and systemic reactions within 30 minutes after each dose
Time Frame
30 minutes
Title
All active AEs within 0-7 days after each dose
Description
Active AE: Local and systemic adverse reactions occurring within 0-7 days after each dose of vaccination
Time Frame
7 days
Title
All non-active collection AEs within 0-28(30) days after each dose
Description
Adverse events other than active AE include solicitation adverse events reported in addition to the specified solicitation time window
Time Frame
28(30) days
Title
All SAEs within 6 months after the last dose is vaccinated
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Calculate geometric mean titer (GMT) of NoV GI.1 and GII.4 IgG antibodies
Time Frame
28 days after the full vaccination
Title
Calculate positive rate of NoV GI.1 and GII.4 IgG antibodies
Time Frame
28 days after the full vaccination
Title
Calculate NoV GI.1 and GII.4 HBGA-blocking antibody titers
Time Frame
28 days after the full vaccination
Title
Calculate NoV GI.1 and GII.4 HBGA-blocking antibody positive rates
Time Frame
28 days after the full vaccination
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
59 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Aged 6 months to 59 years old, can provide legal identification of Chinese population;
Based on medical history and physical examination, determined by the researcher as healthy;
Volunteer legal guardians or trustees have the ability to understand (non-illiterate) research procedures, sign informed consent voluntarily with informed consent, and be able to comply with the requirements of clinical research protocols;
Female subjects of childbearing age were not pregnant at the time of enrollment (negative urine pregnancy test), were not breastfeeding, and had no birth plan within the first 3 months after enrollment; effective contraceptive measures were taken within 2 weeks before enrollment.
Exclusion Criteria:
Axillary body temperature before inoculation on the day of entry> 37.0 ℃;
Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc .;
Have a history of epilepsy, convulsions or convulsions, or a family history of mental illness;
Those who received immunoenhancement or inhibitor therapy within months (continuous oral or instillation for more than 14 days);
Have been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases;
No spleen or spleen function defect caused by any situation;
Severe liver and kidney disease, drug-uncontrollable hypertension (systolic blood pressure> 140mmHg, diastolic blood pressure> 90mmHg), diabetic complications, malignant tumors, various acute diseases or chronic attacks of acute diseases;
Have a history of chronic gastrointestinal diseases, diarrhea or other digestive system diseases, and have had gastroenteritis requiring treatment in the past 7 days;.
Have a history of abnormal coagulation function (such as coagulation factor deficiency, coagulopathy);
Have a history of severe allergic reactions to vaccination; are allergic to any component of the test vaccine;
Live attenuated vaccine within14 days; other vaccines received within 7 days;
Participating in other clinical trials in the near future;
The investigator judges other circumstances that are not suitable for participation in this clinical trial.
In addition to the general exclusion criteria, specific populations should also adhere to the following exclusion criteria:
Premature birth (delivery before the 37th week of pregnancy), low weight (birth <2300g) infants under 24 months of age;
History of salvage, birth apnea, or other causes of salvage, neurological damage, severe chronic disease (such as Down syndrome, sickle cell anemia, or neurological disorders) in children under 24 months of age.
Facility Information:
Facility Name
qixian Center for Disease Control and Prevention
City
Hebi
State/Province
Henan
Country
China
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine
We'll reach out to this number within 24 hrs